

Chiara Ambrogio, PhD

Indirizzo: Molecular Biotechnology Center (MBC)
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
Università di Torino
Via Nizza 52, 10125 Torino
Email: chiara.ambrogio@unito.it



<http://www.linkedin.com/in/chiaraambrogio>
<https://scholar.google.com/citations?user=i2VOkx0AAAAJ&hl=it&oi=ao>
Twitter @AmbrogioLab

Biosketch

Chiara Ambrogio ha conseguito la Laurea Magistrale in Biotecnologie Mediche presso l'Università di Torino nel 2004. Nel 2008 ha completato il Dottorato in Immunologia e Biologia cellulare presso la stessa Università. Per la sua formazione post-dottorato, nel 2009 è stata selezionata con un concorso internazionale dal laboratorio di Mariano Barbacid nel Programma di oncologia molecolare presso il CNIO, Madrid, Spagna. Successivamente si è trasferita al Dipartimento di Oncologia Medica presso il Dana Farber Cancer Institute (DFCI) di Boston (Harvard Medical School) per completare la sua formazione come Senior Scientist nel laboratorio di Pasi Janne (2016-2019). Alla fine del 2019 ha fondato il suo laboratorio indipendente grazie ad un prestigioso finanziamento dalla Armenise-Harvard Foundation (1.000.000 euro, un vincitore all'anno) presso il Centro di Biotecnologie Molecolari (MBC), Università di Torino, dove è anche affiliata come Ricercatore in Biologia Molecolare (Assistant Professor).

Nella sua carriera ha pubblicato più di 40 papers su riviste internazionali di alto livello come *Nature* e *Cell*, (H index= 27), e' relatore in congressi internazionali su oncologia molecolare e medicina traslazionale e ha vinto numerosi premi nazionali ed internazionali, come il Premio under 30 per la ricerca su linfomi dell' Accademia dei Lincei-Roma, conferito dal Presidente Giorgio Napolitano, il postdoc award della AECC (Spanish Association Against Cancer), conferito dalla Regina di Spagna, il Scientific Merit Award della Lung Cancer Research Foundation (LCRF), USA e il premio "Fondazione Lorini" per la ricerca sul cancro under 40.

Educazione

2004-2008: Dottorato (PhD) in Immunologia e Biologia Cellulare, Dipartimento di Scienze Biomediche ed Oncologia Umana, Università di Torino. Titolo di tesi di Dottorato: "*NPM-ALK oncogenic kinase controls morphology and migration in Anaplastic Large Cell Lymphoma cells overcoming TCR signaling deficit by GTPase activation*"

1999-2004: Laurea Magistrale in Biotecnologie Mediche, Università di Torino (110/110 con lode). Titolo di tesi: "*NPM-ALK MODIFIES CYTOSKELETON AND CELLULAR SHAPE BY THE ACTIVATION OF RAC1, CDC42 AND p130CAS*".

Incarico attuale

Dicembre 2019- presente: Ricercatore (Assistant Professor) in Biologia Molecolare, Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino

Formazione scientifica

Aprile 2016-Dicembre 2019: Senior Scientist, Dr Jänne Laboratory Medical Oncology Department, Dana Farber Cancer Institute, Boston, USA

Novembre 2009 – Marzo 2016: Postdoc, Dr Barbacid Laboratory, Experimental Oncology Department, CNIO, Madrid, Spagna

Dicembre 2008 - Novembre 2009: Postdoc, laboratorio del Prof R. Chiarle, CeRMS (Center of Research in Experimental Medicine), Università di Torino

2004-2008: Dottorato (PhD) in Immunologia e Biologia Cellulare, laboratorio del Prof R. Chiarle, CeRMS (Center of Research in Experimental Medicine), Università di Torino

Lingue

Italiano: madre lingua

Inglese: fluente

Spagnolo: fluente

Publicazioni

50 articoli pubblicati in riviste specializzate internazionali (2404 citazioni, h-index: 27, IF cumulativo >500), con ruolo di **primo autore o ultimo autore (=capogruppo)** nelle pubblicazioni evidenziate.

- 1) **Ambrogio C**, Voena C, Manazza AD, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Erba EB, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. *Blood*. 2005 Dec 1. IF: 13.164
- 2) Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, **Ambrogio C**, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. *Blood*. 2006 Jan 15. IF: 13.164
- 3) Voena C, Conte C, **Ambrogio C**, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. *Cancer Res*. 2007 May 1. IF: 9.13
- 4) Berto G, Camera P, Fusco C, Imarisio S, **Ambrogio C**, Chiarle R, Silengo L, Di Cunto F. The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. *J Cell Sci*. 2007 Jun 1. IF: 4.401
- 5) Costa C, Barberis L, **Ambrogio C**, Manazza AD, Patrucco E, Azzolino O, Nielssen P, Circolo E, Altruda F, Prestwich G, Chiarle R, Wymann M, Ridley A, Hirsch E. Constitutive elevation of phosphoinositide 3-Kinase γ activity in mice does not increase tumor susceptibility but reveals a negative feedback loop regulating Rac during leukocyte chemotaxis. *PNAS* 2007 Sept 4. IF: 9.661
- 6) Chiarle R, Voena C, **Ambrogio C**, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat Rev Cancer*. 2008 Jan. IF: 42.784
- 7) Chiarle R, Martinengo C, Mastini C, **Ambrogio C**, D'Escamard V, Forni G, Inghirami G. Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination. *Nat Med* 2008 Jun. IF: 32.621
- 8) Crosetto N, Bienko M, Hibbert RG, Perica T, **Ambrogio C**, Kensche T, Hofmann K, Sixma TK, Dikic I. Human WRNIP1 is localized in replication factories in a UBZ-dependent manner. *J Biol Chem*. 2008 Dec 12. IF: 4.125
- 9) **Ambrogio C**, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G and Chiarle R. Anaplastic Lymphoma Kinase controls cell shape and growth of Anaplastic Large Cell Lymphoma through Cdc42. *Cancer Res* 2008 Nov 1. IF: 9.13
- 10) Barberis L, Pasquali C, Bertschy-Meier D, Cuccurullo A, Costa C, **Ambrogio C**, Vilbois F, Chiarle R, Wymann M, Altruda F, Rommel C, Hirsch E. Leukocyte transmigration is modulated by chemokine-mediated, PI3K γ -dependent phosphorylation of vimentin. *European Journal of Immunology* 2009 Apr. IF: 4.248
- 11) Gonzalo P, Guadamillas MC, Hernández-Riquer MV, Pollán A, Grande-García A, Bartolomé RA, Vasanji A, **Ambrogio C**, Chiarle R, Teixidó J, Risteli J, Apte SS, del Pozo MS, and Arroyo AG. Membrane type 1-matrix metalloproteinase contributes to macrophage fusion through the regulation of the Rac1 signaling pathway. *Dev Cell*. 2010 Jan 19. IF: 9.616
- 12) **Ambrogio C**, Martinengo C, Voena C, Tondat F, Francia di Celle P, Inghirami G and Chiarle R. NPM-ALK oncogenic tyrosine kinase controls T cell identity by transcriptional and epigenetic silencing in lymphoma cells. *Cancer Res* 2009 Nov 15. IF: 9.13
- 13) Riera L, Lasorsa E, **Ambrogio C**, Surrenti N, Voena C, Chiarle R. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. *J Biol Chem*. 2010 Aug 20. IF: 4.125
- 14) Boselli D, Ragimbeau J, Orlando L, Cappello P, Capello M, **Ambrogio C**, Chiarle R, Marsili G, Battistini A, Giovarelli M, Pellegrini S, Novelli F. Expression of IFN γ mutated in a dileucine internalization motif reinstates IFN γ signaling and apoptosis in human T lymphocytes. *Immunol Lett*. 2010 Nov 30. IF: 1.85
- 15) **Di Paolo D***, **Ambrogio C***, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, Ribatti D, Allen TM, Chiarle R, Ponzoni M, Perri P. Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. *Mol Ther*. 2011 Aug 9. ***equally contributed.** IF: 6.938
- 16) Bosio Y, Berto G, Camera P, Bianchi F, **Ambrogio C**, Claus P, Di Cunto F. PPP4R2 regulates neuronal cell differentiation and survival, functionally cooperating with SMN. *Eur J Cell Biol*. 2012 Aug. IF: 5.22
- 17) Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, Pellegrino E, Todaro M, Recupero D, Tabbò F, **Ambrogio C**, Martinengo C, Bonello L, Pulito R, Hamm J, Chiarle R, Cheng M, Ruggeri B, Medico E, Inghirami G. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. *Oncogenesis*. 2013 Apr 8. IF: 4.722
- 18) Piazza R, Magistroni V, Mogavero A, Andreoni F, **Ambrogio C**, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. *Neoplasia*. 2013 May. IF: 5.006

- 19) Martinengo C, Poggio T, Menotti M, Scalzo MS, Mastini C, **Ambrogio C**, Pellegrino E, Riera L, Piva R, Ribatti D, Pastorino F, Perri P, Ponzoni M, Wang Q, Voena C, Chiarle R. ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. *Cancer Res.* 2014 Sep 5. IF: 9.13
- 20) **Ambrogio C**, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaría D, Villanueva A. Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts. *Cancer Res.* 2014 Sep 12. IF: 9.13
- 21) **Ambrogio C**, Stern P, Scuoppo C, Kranz H, Barbacid M, Santamaría D. Lentiviral-based approach for the validation of cancer therapeutic targets in vivo. *Biotechniques.* 2014 Oct 1. IF: 2.098
- 22) Blasco RB, Karaca E, **Ambrogio C**, Cheong TC, Karayol E, Minero VG, Voena C, Chiarle R. Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. *Cell Rep.* 2014 Nov 20. IF: 8.282
- 23) Lopez-Contreras AJ, Specks J, Barlow JH, **Ambrogio C**, Desler C, Vikingsson S, Rodrigo-Perez S, Green H, Rasmussen LJ, Murga M, Nussenzweig A, Fernandez-Capetillo O. Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. *Genes Dev.* 2015 Apr 1. IF: 9.413
- 24) García-Beccaria M, Martínez P, Méndez-Pertuz M, Martínez S, Blanco-Aparicio C, Cañamero M, Mulero F, **Ambrogio C**, Flores JM, Megias D, Barbacid M, Pastor J, Blasco MA. Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage. *EMBO Mol Med.* 2015 May 13. IF: 9.249
- 25) Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo ME, **Ambrogio C**, Wang Q, Minero VG, Poggio T, Martinengo C, D'Amico L, Panizza E, Mologni L, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R. Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. *Cancer Immunol Res.* 2015 Sep 29. IF: 9.188
- 26) **Ambrogio C**, Cámara JA, Nieto P, Santamaría D, Mulero F. Analysis of Murine Lung Tumors by Micro PET-CT Imaging. *Bio-protocol*, 2015 December.
- 27) Ceccon M, Merlo ME, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, **Ambrogio C**, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. *Oncogene.* 2016 Jul 21. IF: 6.854
- 28) Choudhari R, Minero VG, Menotti M, Pulito R, Brakebusch C, Compagno M, Voena C, **Ambrogio C***, Chiarle R*. Redundant and non-redundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. *Blood.* 2016 Jan 8. ***Co-last author.** IF: 13.164
- 29) **Ambrogio C***, Gómez-López G, Falcone M, Villanueva A, Crosetto N, Blasco R, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Serrano M, Hidalgo M, Santamaría D*, Barbacid M*. Combined inhibition of Ddr1 and Notch signaling as an effective therapeutic strategy for K-Ras-driven/p53-null lung adenocarcinomas. *Nat Med.* 2016 Feb 8. ***Co-corresponding author.** IF: 32.621
(Referred by Research Watch in Cancer Discovery: Dual Therapy with DDR1 and Notch Inhibitors Kills KRAS-Mutant Lung Tumors. *Cancer Discov.* 2016 Feb 18.)
- 30) **Ambrogio C***, Nadal E, Villanueva A, Gómez-López G, Cash TP, Barbacid M, Santamaría D. KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. *ESMO Open.* 2016 Sept 1. ***Corresponding author.**
- 31) **Ambrogio C***, Barbacid M, Santamaría D*. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. *Oncogene.* 2016 Oct 24. ***Co-corresponding author.** IF: 6.854
- 32) **Ambrogio C**, Santamaría D. DDR1 and Notch: a multifaceted synergy. *Translational Cancer Research.* 2016 Dec. IF: 1.757.
- 33) Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langelotto F, **Ambrogio C**, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. *Nature.* 2017 Feb 23. IF: 40.137
- 34) Kohler J, Catalano M, **Ambrogio C**. Back to the bench? MEK and ERK inhibitors for the treatment of KRAS mutant lung adenocarcinoma. *Curr Med Chemistry.* 2017 May 29. IF: 3.469
- 35) Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, **Ambrogio C**, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Jänne PA, Scott DA, Westover KD, Gray NS. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. *Cell Chem Biol.* 2017 Jul. IF: 5.592
- 36) Nieto P, **Ambrogio C**, de Esteban L, Gómez-López G, Blasco MT, Yao Z, Marais R, Rosen N, Chiarle R, Pisano DG, Barbacid M, Santamaría D. A B-Raf kinase inactive mutant induces lung adenocarcinoma. *Nature.* 2017 Aug 2. IF: 40.137
- 37) **Ambrogio C***, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD, Jänne PA*. KRAS dimerization impacts MEK inhibitor sensitivity

and oncogenic activity of mutant KRAS. *Cell*. 2018 Jan 4. ***Co-corresponding author**. IF: 31.398

- 38) **Ambrogio C**, Darbo E, Lee SW, Santamaria D. A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance. *Cell Adhesion & Migration*, 2018 March 5. IF: 3.566
- 39) Abravanel DL, Nishino M, Sholl LM, **Ambrogio C**, Awad MM. An acquired NRAS Q61K mutation in BRAF V600E-mutant lung adenocarcinoma resistant to dabrafenib plus trametinib. *J Thorac Oncol*. 2018 Apr 6. IF: 10.336
- 40) Li S, Liu S, Deng J, Akbay EA, Hai J, **Ambrogio C**, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, Gao P, Wang X, Paweletz CP, Herter-Sprie GS, Chen T, Gutierrez Quiceno L, Zhang Y, Merlino AA, Quinn MM, Zeng Y, Yu X, Liu Y, Fan L, Aguirre AJ, Barbie DA, Yi X, Wong KK. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer. *Clin Cancer Res*. 2018 Jun 26. IF: 10.199
- 41) Kobayashi Y, **Ambrogio C**, Mitsudomi T. Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. *Transl Lung Cancer Res* Jul 2018. IF: 4.806
- 42) Dagogo-Jack I, Martinez P, Yeap BY, **Ambrogio C**, Ferris LA, Lydon CA, Nguyen T, Jessop N, Iafrate JA, Johnson BE, Lennerz JK, Shaw AT, Awad MM. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer. *Clin Cancer Res*. 2018 Sep 17. pii: clincanres.2062.2018. doi: 10.1158/1078-0432.CCR-18-2062. IF: 10.199
- 43) Menotti M, **Ambrogio C**, Cheong TC, Pighi C, Mota I, Cassel SH, Compagno M, Wang Q, Dall'Olio R, Minero V, Poggio T, Sharma GG, Patrucco E, Mastini C, Choudhari R, Pich A, Zamo A, Piva R, Giliani S, Mologni L, Collings CK, Kadoch C, Gambacorti-Passerini C, Notarangelo LD, Anton ID, Voena C, Chiarle R. Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. *Nat Med*. 2018 Dec 3. <https://doi.org/10.1038/s41591-018-0262-9> IF: 32.621
- 44) Wang H, Lv Q, Xu Y, Cai Z, Zheng J, Chen X, Dai Y, Jänne PA, **Ambrogio C*** and Köhler J*. An integrative pharmacogenomics analysis identifies CK2 alpha as a promising therapeutic target in KRAS(G12C) mutant lung cancer. *EBioMedicine*. 2019 Nov;49:106-117. doi: 10.1016/j.ebiom.2019.10.012. Epub 2019 Oct 23. ***Co-last author**. IF: 6.68
- 45) **Zhou Z***, **Ambrogio C***, Bera AK, Li Q, Li X, Li L, Son J, Gondi S, Li J, Campbell E, Jin H, Okoro JJ, Xu C, Jänne PA, Westover KD. KRASQ61H signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer. *Cancer Res*. 2020 Jun 30. ***equally contributed**. IF: 9.13
- 46) Nokin MJ, Darbo E, Travert C, Drogat B, Lacouture A, San José S, Cabrera N, Turcq B, Prouzet-Mauleon V, Falcone M, Villanueva A, Wang H, Herfs M, Mosteiro M, Jänne PA, Pujol JL, Maraver A, Barbacid M, Nadal E, Santamaria D and **Ambrogio C**. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. *JCI Insight*. 2020 Aug 6. IF: 6.014.
- 47) Marmarelis ME, Chiarle, **Ambrogio C*** and Aggarwal C*. A LIBRETTO to orchestrate targeted therapy. *Nature Cancer*, 2020 Nov 17. ***Co-last author**.
- 48) Nokin MJ, **Ambrogio C**, Nadal E, Santamaria D. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. *Trends in Cancer*, 2020 Dec 9. IF: 8.88.
- 49) Kramer-Drauberg M and **Ambrogio C**. Discoveries in the redox regulation of KRAS. *The International Journal of Biochemistry & Cell Biology*, 2020 Dec 10. IF: 3.673.
- 50) Köhler J, Zhao Y, Li J, Gokhale PC, Tiv HL, Knott AR, Wilkens MK, Soroko KM, Lin M, **Ambrogio C**, Musteanu M, Ogino A, Choi J, Bahcall M, Bertram AA, Chambers ES, Paweletz CP, Bhagwat SV, Manro JR, Tiu RV, Janne PA. ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer. *Mol Cancer Ther*. 2021 Feb 3. IF: 5.040.
- 51) Mysore VP, Zhou Z, **Ambrogio C**, Wang Q, Okoro J, Jänne PA, Westover KD, Shan Y, Shaw DE. Structural model of a Ras-Raf signalosome. *Submitted*.

Congressi (relatore)

- 1) "XII Meeting of European Association for Haematopathology" in Salonicco-Greece (2004). *Oral Presentation*.
- 2) 2005 ABCD Meeting (Cellular Biology and Differentiation Association), Certosa di Pontignano, (18-19 March 2005). *Oral presentation*.
- 3) "XIII Meeting of European Association for Haematopathology" in Vienna-Austria (2006). *Oral presentation*.
- 4) 2007 ABCD Meeting (Cellular Biology and Differentiation Association), Roma (30-31 March 2007). *Oral presentation*.
- 5) Third SIBBM Meeting (Italian Society of Biophysics and Molecular Biology), Torino (25-27 June 2007). *Oral presentation*.
- 6) CNIO Cancer Conference: "Molecular mechanisms in lymphoid neoplasm", Madrid (February 2007). *Oral presentation*.
- 7) Mechanisms and Models of Cancer, Salk Institute, La Jolla, CA, USA, (August 12-16, 2009). *Oral presentation*.

- 8) EACR-22 meeting, "From Basic Research to Personalized Cancer Treatment", Barcelona, Spain, (July 7-10, 2012). *Oral presentation.*
- 9) NATURE–CNIO CANCER SYMPOSIUM: "Frontiers in Tumor Heterogeneity and Plasticity", Madrid, Spain, (October 28-30, 2013). *Oral presentation.*
- 10) EACR-23 meeting, "From Basic Research to Personalized Cancer Treatment", Munich, Germany, (July 5-8, 2014). *Poster presentation (Winner of the Best Poster presentation award.)*
- 11) CNIO-Frontiers Meeting: "NEW TRENDS IN ANTICANCER DRUG DEVELOPMENT", Madrid, Spain, (March 22-25, 2015). *Oral presentation.*
- 12) EACR-AACR-SIC 2015 Conference, "From cancer biology to the clinic", Firenze, Italy, (June 20-23, 2015). *Oral presentation.*
- 13) ESMO 2016 Personalized Medicine Symposium, "Signaling Pathways in Cancer", Barcelona, Spain, (March 4-5, 2016). *Invited speaker.*
- 14) Tongji University, Shanghai, School of Life Science and Technology Program, Shanghai, China, (September 12-13, 2016). *Invited speaker.*
- 15) ESMO 2017-EACR, Madrid, Spain (September 8-12, 2017). *Oral presentation.*
- 16) 2017 NCI RAS Initiative Symposium, Frederick, USA (December 6-8, 2017). *Oral presentation.*
- 17) 2018 AACR RAS Meeting, San Diego, USA (December 9-12, 2018). *Invited speaker.*
- 18) 2018 RAS Symposium "THE RAS SUPERFAMILY AND RELATED PATHWAYS IN HEALTH AND DISEASE", Santander, Spain (May 16-18, 2019). *Invited speaker.*
- 19) RAS Initiative, NIH, Frederick, (July 18, 2019). *Invited speaker.*
- 20) "Rising Stars seminar series", NIH Bethesda, (July 19, 2019). *Invited speaker.*
- 21) HansonWade RAS-Targeted Drug Discovery Summit, Boston, (September 16-19, 2019). *Invited speaker.*
- 22) University of Copenhagen, (November 7, 2019). *Invited speaker.*
- 23) Sixth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, San Diego, USA (January 11 - 14, 2020). *Invited speaker.*
- 24) University of Zurich, (February 12, 2020). *Invited speaker.*
- 25) HansonWade, 2nd RAS-Targeted Drug Discovery Summit (Virtual), Boston, (September 14-16, 2020). *Invited speaker.*
- 26) 9th Annual PREDICT Tumor Models Meeting (Virtual), London, December 1-3, 2020. *Invited speaker.*
- 27) Precision Medicine for RAS pathway mutations in cancer (Virtual), Manchester, (December 8-9, 2020). *Keynote lecture.*
- 28) IASLC 2020 World Conference on Lung Cancer (Virtual), Singapore, (January 28-31, 2021), *Invited speaker.*
- 29) INSIDE - The dark side of the cell (Virtual), Vienna, (February 11-12, 2021), *Invited speaker.*

Appartenenza a società scientifiche nazionali ed internazionali

2014-presente: Member, European Association for Cancer Research (EACR)

2016-presente: Member, European Society of Medical Oncology (ESMO)

2018-presente: Active Member, American Association for Cancer Research (AACR)

2019-presente: Member, Spanish Association Research Against Cancer (ASEICA)

Attività Editoriale:

Ad hoc Reviewer:

- Nature Medicine
- Cancer Research
- Clinical Cancer Research
- PLoS Computational Biology
- Science Signaling
- Oncotarget
- Journal of Molecular Biology
- EBioMedicine (Lancet)
- Frontiers in Oncology
- Molecular Cancer Therapeutics
- Leukemia Research
- Journal of Cancer Research and Clinical Oncology
- Journal of Oncology

Altri ruoli editoriali

2016- presente: Editorial Board, Bio-Protocol

2017- presente: Editorial Board, Frontiers in Bioscience

2020- presente: Editorial Board, Cancers

Attività di revisore:

2/2018- presente: Grant Reviewer, The Wellcome trust DBT India Alliance

7/2018- presente: Grant Reviewer, FWO Foundation, Flanders

9/2018- presente: Grant Reviewer, National Science Centre, Poland

1/2020- presente: Grant Reviewer, Medical Research Council, UK

Premi

2020: Premio "Marcellina Gilli" della Consulta Regionale Piemonte

2020: Nominata fra i "40 under 40" 2020 da Fortune (Italia)

2019: Premio "Premio Chianello" per la Ricerca Oncologica

2019: Premio "Fondazione Lorini per la ricerca sul cancro under-40

2018: Scientific Merit Award della Lung Cancer Research Foundation (LCRF)

2014: Premio Com.It.Es (Organization of Italians abroad), categoria "Università e Ricerca".

2014: Premio per la miglior presentazione poster EACR-23 meeting, "From Basic Research to Personalized Cancer Treatment", Monaco, Germania.

2012: Proffered Paper Award EACR-22, Barcellona, Spagna.

2012: AECC (Spanish Association Against Cancer) Postdoctoral Award, conferito personalmente dalla Regina di Spagna

2009: Premio "Silvia Fiocco" per la ricerca su linfomi e leucemie, Accademia dei Lincei-Roma, conferito personalmente dal Presidente della Repubblica Giorgio Napolitano.

2008: Premio "Fondazione Costa" per la ricerca sul cancro.

2007: Premio SIBBM (Società Italiana di Biofisica e Biologia Molecolare)

Progetti e Finanziamenti

2021-2026: ERC Consolidator Grant, budget finanziato €2.000.000.

2021-2022: SRA (Scientific Research Agreement) Revolution Medicine, \$300.000.

2020-2023: Harvard-Armenise Career Development Grant, budget finanziato, \$1.000.000.

2020-2023: "Ramon y Cajal" Excellence Grant, Ministero della Salute (Spagna), primo assoluto, €500.000 (n/a).

2018-2020: Principal Investigator, Lung Cancer Research Foundation (LCRF) budget finanziato \$150.000.

2017-2018: Principal Investigator of the Wong Funds in Translational Oncology (DFCI, Boston), budget finanziato \$150.000.

2016-2018: Stand Up To Cancer, Lung Cancer Dream Team.

2012-2017: AECC (Spanish Association Against Cancer) Postdoctoral Fellowship (5 anni).

2009-2011: CNIO-Caja Navarra International Postdoctoral Program

2009-2012: Principal Investigator di **MFAG-2009** finanziato da AIRC (Associazione Italiana per la Ricerca sul Cancro), budget finanziato €150.000.

Torino, 19 febbraio 2021

In fede,

